Eli Lilly
-
healthSingle Gene-Editing Dose Slashes Bad Cholesterol by 62% in Early Trial
A one-time infusion of VERVE-102 gene-editing therapy reduced LDL cholesterol by 62% in a small Phase I trial, offering hope for a permanent fix.
-
healthFrance Becomes First EU Country to Reimburse Weight-Loss Drugs
France will start covering costs of Wegovy and Mounjaro from June 15, a historic move making it the first EU nation to offer permanent reimbursement for GLP-1 weight-loss medications.
-
healthEli Lilly Invests $3.83 Billion in Vaccine Biotechs
Eli Lilly acquires three vaccine biotechs for up to $3.83bn to target shingles, antimicrobial resistance, and Epstein-Barr virus.
-
financeGoldman Flags Risk in AI-Driven Rally, Picks 'Insensitive' Stocks
Goldman Sachs warns market concentration around AI creates risk, unveils portfolio of stocks with positive earnings but low AI sensitivity.
-
healthPeptide Craze Surges Beyond GLP-1s as FDA Faces Pressure to Ease Access
The peptide market is exploding amid regulatory tensions, with the FDA set to consider loosening restrictions on several peptides this summer.
-
healthRetatrutide: The New Obesity Drug That Could Spare Muscle Mass During Weight Loss
GLP-1 triple agonist retatrutide may offer significant weight loss while preserving lean muscle, according to neuroscientist Andrew Huberman.
-
healthGlobal Obesity Crisis Widens as Treatment Access Lags in Hardest-Hit Regions
New research reveals obesity rates are accelerating in developing nations while GLP-1 drugs remain concentrated in wealthier countries, highlighting a critical equity gap.
-
techMichael Dell’s Keynote: AI Is the New Enterprise Infrastructure
Michael Dell tells industry leaders that AI has moved into the operational core of business, urging a shift from cloud dependency to hybrid AI.